First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
Mauricio G. Cohen(Santa Ana College), Richard C. Becker(Clinical Research Institute), Adam B. Greenbaum(Brigham and Women's Hospital), Drew A. Purdy(St. Michael's Hospital), Steven L. Zelenkofske(Novartis (Switzerland)), Robert A. Harrington(Clinical Research Institute), Joseph S. Rossi(University of North Carolina at Chapel Hill), John H. Alexander(Ohio State University Hospital), Mark Y. Chan(National University Heart Centre Singapore), Christopher P. Rusconi(University of North Carolina at Chapel Hill), Edward T.A. Fry, Liliana Grinfeld(University of North Carolina at Chapel Hill), Shelley K. Myles(University of North Carolina at Chapel Hill), Laura H. Aberle(Clinical Research Institute), Ross M. Tonkens(University of North Carolina at Chapel Hill)
Cited by 98
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k